Mucormycosis, previously called ‘zygomycosis’, also known as ‘black fungus disease ‘in online or print media after its epidemic in India during the COVID-19 pandemic, is a serious but rare fungal infection caused by the mucormycetes group of fungi. It is a rapidly destructive necrotizing fungal infection usually seen in diabetics and also in other immunocompromised patients. The group includes fungi belonging to the genera Lichtheimia, Mucor, Rhizomucor, Cunninghamella, Saksenaea, Apophysomyces, Cokeromyces, Actinomucor, and Syncephalastrum.
Black fungus is a ‘misnomer’ because Mucorales are hyaline fungi. There are already categories of black fungi already described in the medical literature causing tinea nigra, chromoblatomycosis, phaeohyphomycosis.
Rhizopus arrhizus (formerly Rhizopus oryzae) is the most common etiological agent. It is the third invasive mycosis in order of importance after candidiasis and aspergillosis and has an overall mortality rate of 50%.
It is caused by exposure to mucor which is ubiquitous in the environment and is found in soil, plants, manure, decaying fruits and vegetables, air, and even as commensal in the nose and mucus of healthy people.
People with a weakened immune system are at higher risk of acquiring mucormycosis. Factors predisposing to the infection include conditions such as;
- Severely immunocompromised individuals, such as cancer patients or people with HIV/AIDS.
- Immunosuppression by use of steroids ( steroids are drugs that slow or stop the immune system processes that trigger inflammation) as in the treatment of COVID-19
- Hematological malignancies,
- Hematopoietic stem cell transplantation
- Organ transplantation,
- Intravenous drug use,
- Neonatal prematurity and malnourishment
Immunocompetent patients can also be affected, when the spores of the fungus are directly inoculated in the skin, as a result of trauma or burns.
Mucormycetes enter the body either by inhalation of airborne spores, percutaneous inoculation or ingestion. Once the spores reach the lungs or subcutaneous tissues, they are destroyed by the first line of defence, mononuclear and polynuclear phagocytes in healthy individual.
But when an immunocompromised host breathes in the spores of mucormycetes, the defence system is hampered, and it cause an infection commonly in the lungs or sinuses, which can spread to other parts of the body and cause disseminated infection.
Since mucormycosis affects many parts of the body, clinical manifestations are classified depending upon the site of infection and symptoms depend upon the part affected.
Rhinocerebral (sinus and brain) mucormycosis is an infection in the sinuses that can spread to the brain. This form of mucormycosis is most common in people with uncontrolled diabetes mellitus, kidney transplant and leukaemia, but is rare in solid-organ or haematopoietic stem-cell recipients and occasional in patients with HIV infection.
Clinical manifestations may start with necrosis of the palate or sinuses, which may progress towards the orbit before reaching intra-cranial structures.
Symptoms of rhinocerebral (sinus and brain) mucormycosis include:
- One-sided facial swelling
- Nasal or sinus congestion
- Black lesions on nasal bridge or upper inside of mouth that quickly become more severe
Pulmonary (lung) mucormycosis
Invasion of the lung is the second most common clinical manifestation and follows the inhalation of spores. It is the common type of mucormycosis in people with hematological malignancy with neutropenia and in organ transplant or a stem cell transplant cases.
Symptoms of pulmonary (lung) mucormycosis include:
- Chest pain
- Shortness of breath
It is difficult to differentiate between invasive aspergillosis and pulmonary mucormycosis. Both show similar symptoms and on radiological presentation vascular invasion and thrombosis, followed by tissue necrosis, is seen in both cases.
Gastrointestinal mucormycosis occurs through ingestion of spores possibly from fermented milk, dried bread products, fermented porridges, and alcoholic beverages derived from infected corn. It can also be contracted from from infected tongue depressors at physician clinics.
Gastrointestinal mucormycosis most commonly affects stomach, followed by colon, small intestine and oesophagus.
Symptoms of gastrointestinal mucormycosis include:
- Abdominal pain
- Nausea and vomiting
- Gastrointestinal bleeding
Cutaneous (skin) mucormycosis
Cutaneous mucormycosis is often acquired by direct inoculation, through breaks in the skin (eg after surgery, burns, motor vehicle accidents) by contaminated dressings, and insulin injection sites. Outbreaks of mucormycosis in healthcare centers are common due to contaminated adhesive tape, wooden tongue depressors, ostomy bags, and building construction contamination.
This is the most common form of mucormycosis among immunocompetent host.
Cutaneous mucormycosis can be classified as primary and secondary.
- In primary disease, the skin is infected by direct inoculation. and in
- In secondary form, infection occurs by dissemination from other locations, more commonly from a rhino cerebral infection. Secondary cutaneous mucormycosis be further be subcategorized according to the pattern of infection as localized, deep, or disseminated.
The most affected areas of the skin are the arms and legs. Other locations include the scalp, face, thorax, back, abdomen, perineum, breast, neck and gluteal area.
Symptoms of cutaneous mycormycosis
- Begins as erythema and induration at the site of inoculation which manifest typically as a black eschar with central ulceration
- Other symptoms include pain, warmth, excessive redness, or swelling around a wound.
Disseminated mucormycosis (DM)
Disseminated mucormycosis (DM) often involves two or more non continuous organ systems. The infection spreads through the bloodstream and affects the brain, but also can affect other organs such as the spleen, heart, kidney and skin.
Disseminated cutaneous mucormycosis is exceedingly rare and deadly, with a mortality rate of 90–100%
Symptoms are non-specific and varies depending on the site of attack. For e.g Patients with disseminated infection in the brain can develop mental status changes or coma whereas dissemination to the skin results in erythematous lesions.
Other clinical manifestations:
- Mucormycosis may be the cause of endocarditis in natural or prosthetic valves.
- Osteomyelitis is another rare form of mucormycosis, and bone lesions are usually adjacent to other forms of mucormycosis.
- Peritoneal mucormycosis may occur in patients undergoing continuous ambulatory peritoneal dialysis.
- Isolated mucormycosis of the central nervous system (CNS) may develop in immunocompromised patients and in users of illicit intravenous drugs
- Renal mucormycosis occurs in the setting of illicit intravenous drug use or contamination of a central venous catheter.
Treatment of mucormycosis
The successful treatment of mucormycosis depends on 1) early diagnosis of mucormycosis; 2) reversal of underlying predisposing risk factors, if possible; 3) surgical debridement (extensive surgical debridement is must for removing the necrotic tissue for better circulation and penetration of antifungal drugs) where applicable, and 4) prompt antifungal therapy.
For monotherapy options,
- Lipid formulations of amphotericin B deoxycholate, lipid polyenes are used.
- Posaconazole is an option for salvage therapy in patients with mucormycosis who were refractory to or intolerant of polyenes.
Fluconazole, voriconazole, and itraconazole do not have reliable activity against mucormycosis
- Combination of polyene-caspofungin therapy has shown significantly improved outcomes in patients with rhino-orbital and rhino-orbital-cerebral mucormycosis compared to polyene monotherapy.
- Combination of deferasirox (iron chelator) – liposomal amphotericin B (LAmB) therapy synergistically improved survival in animal models.
- Proinflammatory cytokines, such as interferon (IFN)-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF), enhance the ability of granulocytes to damage the agents of mucormycosis
- Adjunctive immune therapy with recombinant granulocyte colony-stimulating factor (G-CSF) and GM-CSF, or with recombinant IFN-γ, has been used successfully in conjunction with lipid formulations of amphotericin B in treatment of mucormycosis.
References and further readings:
- E. Bouza, P. Munoz and J. Guinea 2006 Mucormycosis: an emerging disease? Clin Microbiol Infect; 12 (suppl 7): 7–23
- Castrejón-Pérez, A. D., Welsh, E. C., Miranda, I., Ocampo-Candiani, J., & Welsh, O. (2017). Cutaneous mucormycosis. Anais brasileiros de dermatologia, 92(3), 304–311. https://doi.org/10.1590/abd1806-4841.20176614
- Spellberg, B., & Ibrahim, A. S. (2010). Recent advances in the treatment of mucormycosis. Current infectious disease reports, 12(6), 423–429. https://doi.org/10.1007/s11908-010-0129-9.